ESR1 and neoplasm: No significant difference in tumor stages was observed between the two subtypes, but a larger proportion of stage II patients were found for the ER-negative subtype compared with that for the ER-positive group in TCGA (62.6% vs 54.5%), which was consistent with that in SEER (Table 1).